Dry Eye Syndromes

Ophthalmology
6
Pipeline Programs
11
Companies
14
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
1
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
HydroxypropylmethylcellulosePhase 41 trial
Active Trials
NCT01280110Completed44Est. Jan 2012
Thea Pharma
Thea PharmaMA - Waltham
2 programs
1
T2750Phase 31 trial
T2259N/A1 trial
Active Trials
NCT03874429CompletedEst. Mar 2021
NCT01568593CompletedEst. Mar 2013
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
1
1
Ecabet 2.83%Phase 2/31 trial
EcabetPhase 21 trial
Active Trials
NCT00370747Completed162Est. Jun 2007
NCT00198536Completed159Est. Dec 2005
Alcon
AlconFORT WORTH, TX
2 programs
1
Systane COMPLETE Lubricant Eye DropsPhase 21 trial
Systane CompleteN/A1 trial
Active Trials
NCT03706443CompletedEst. Feb 2019
NCT06188260CompletedEst. Nov 2024
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
XiidraPhase 11 trial
Active Trials
NCT07040826CompletedEst. Apr 2023
S
SantenCA - Emeryville
2 programs
Alocross 0.2% Unit DoseN/A1 trial
Cationorm ProN/A1 trial
Active Trials
NCT04685109Active Not Recruiting80Est. Sep 2026
NCT04701086Completed83Est. Apr 2025
Marinomed Biotech
Marinomed BiotechAustria - Korneuburg
1 program
CarrageloseN/A1 trial
Active Trials
NCT06262100Completed30Est. Jul 2024
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Eye Drops with Experimental PreservativeN/A1 trial
Active Trials
NCT01434277Completed44Est. Apr 2011
Lumenis
LumenisAustralia - Chatswood
1 program
M22-IPLN/A1 trial
Active Trials
NCT02621593Completed44Est. Jan 2017
Opko Health
Opko HealthMIAMI, FL
1 program
Vis Glyc NeoN/A1 trial
Active Trials
NCT04063644CompletedEst. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.Hydroxypropylmethylcellulose
Thea PharmaT2750
Bausch + LombEcabet 2.83%
AlconSystane COMPLETE Lubricant Eye Drops
Bausch + LombEcabet
Qilu PharmaceuticalXiidra
Marinomed BiotechCarragelose
SantenCationorm Pro
SantenAlocross 0.2% Unit Dose
Opko HealthVis Glyc Neo
Thea PharmaT2259
AlconSystane Complete
LumenisM22-IPL
Johnson & JohnsonEye Drops with Experimental Preservative

Clinical Trials (14)

Total enrollment: 646 patients across 14 trials

NCT01280110Merck & Co.Hydroxypropylmethylcellulose

The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients

Start: Mar 2011Est. completion: Jan 201244 patients
Phase 4Completed
NCT01568593Thea PharmaT2750

Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome

Start: Mar 2012Est. completion: Mar 2013
Phase 3Completed
NCT00198536Bausch + LombEcabet 2.83%

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Start: Apr 2005Est. completion: Dec 2005159 patients
Phase 2/3Completed
NCT06188260AlconSystane COMPLETE Lubricant Eye Drops

Efficacy of a New Nanoemulsion Artificial Tear Targeting Dry Eye Disease

Start: Jan 2024Est. completion: Nov 2024
Phase 2Completed
NCT00370747Bausch + LombEcabet

Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

Start: Sep 2006Est. completion: Jun 2007162 patients
Phase 2Completed
NCT07040826Qilu PharmaceuticalXiidra

Lifitegrast Eye Drops in Healthy Subjects：Phase I Study

Start: Dec 2022Est. completion: Apr 2023
Phase 1Completed
NCT06262100Marinomed BiotechCarragelose

Lubricating Effectiveness of Carragelose Eye Drops in Patients Affected by Mild to Moderate Dry Eye

Start: Jan 2024Est. completion: Jul 202430 patients
N/ACompleted
NCT04701086SantenCationorm Pro

3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Start: Sep 2021Est. completion: Apr 202583 patients
N/ACompleted
NCT04685109SantenAlocross 0.2% Unit Dose

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Start: May 2021Est. completion: Sep 202680 patients
N/AActive Not Recruiting
NCT04063644Opko HealthVis Glyc Neo

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Start: May 2019Est. completion: Dec 2020
N/ACompleted
NCT03874429Thea PharmaT2259

Efficacy of T2259 in DED

Start: Apr 2019Est. completion: Mar 2021
N/ACompleted
NCT03706443AlconSystane Complete

Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops

Start: Dec 2018Est. completion: Feb 2019
N/ACompleted
NCT02621593LumenisM22-IPL

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

Start: Oct 2015Est. completion: Jan 201744 patients
N/ACompleted
NCT01434277Johnson & JohnsonEye Drops with Experimental Preservative

Safety Evaluation of a New Preservative in a Lubricating Eye Drop

Start: Apr 2011Est. completion: Apr 201144 patients
N/ACompleted

Related Jobs in Ophthalmology

Lead Data Manager

Genomics
Remote
4h ago

Cleanroom and Laboratory Technician

SAB BIO
4h ago

Product Specialist

Johnson & Johnson
Hangzhou, Zhejiang, China
20h ago

BM 喀什 PSR HY

Johnson & Johnson
Urumqi, Xinjiang, China
20h ago

Site Delivery Leader MLL

Johnson & Johnson
Gent, East Flanders, Belgium
20h ago

Clinical Operations Manager

Johnson & Johnson
Irvine, California, United States of America
20h ago
$117K - $201K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
11 companies competing in this space

Related Indications

Myopia(127)Cataract(116)Open-Angle Glaucoma(102)Glaucoma(92)Dry Eye(74)Age-Related Macular Degeneration(73)Dry Eye Disease(43)Neovascular Age-related Macular Degeneration(40)Macular Degeneration(37)Diabetic Retinopathy(25)